CAJ | 학술논문

目的：检测分析骨转移为首发的非小细胞肺癌中ER-β的表达,分析其与临床预后相关性。方法应用免疫组织化学方法检测经病理证实骨转移为首发的非小细胞肺癌肿瘤组织标本中ER-β的表达,利用χ2检验检测组间表达差异,生存率单因素采用Kaplan-Meier法及Log-rank方法分析,多因素采用COX回归模型进行分析。结果46例骨转移为首发的非小细胞肺癌中ER-β总阳性78.3%,χ2检验未见性别、年龄、病理类型、骨转移灶数目、有无骨外其他部位转移、ALK及CEA影响ER-β表达,各组阳性率差异无统计学意义。多因素分析显示ER-β为影响该类患者预后的独立影响因素(P=0．035),单因素分析可见ER-β阳性表达组的生存时间明显长于阴性表达组,差异有统计学意义(P<0．05)。另外ER-β阳性表达时腺癌、单发骨转移患者能获得较长的生存时间,差异有统计学意义( P<0．05)。结论骨转移为首发的非小细胞肺癌 ER-β表达阳性率高, ER-β阳性表达的患者预后明显好于阴性患者,且其可能为影响患者预后的独立影响因素,ER-β的阳性表达可能与腺癌及单发骨转移患者的预后相关。
목적：검측분석골전이위수발적비소세포폐암중ER-β적표체,분석기여림상예후상관성。방법응용면역조직화학방법검측경병리증실골전이위수발적비소세포폐암종류조직표본중ER-β적표체,이용χ2검험검측조간표체차이,생존솔단인소채용Kaplan-Meier법급Log-rank방법분석,다인소채용COX회귀모형진행분석。결과46례골전이위수발적비소세포폐암중ER-β총양성78.3%,χ2검험미견성별、년령、병리류형、골전이조수목、유무골외기타부위전이、ALK급CEA영향ER-β표체,각조양성솔차이무통계학의의。다인소분석현시ER-β위영향해류환자예후적독립영향인소(P=0．035),단인소분석가견ER-β양성표체조적생존시간명현장우음성표체조,차이유통계학의의(P<0．05)。령외ER-β양성표체시선암、단발골전이환자능획득교장적생존시간,차이유통계학의의( P<0．05)。결론골전이위수발적비소세포폐암 ER-β표체양성솔고, ER-β양성표체적환자예후명현호우음성환자,차기가능위영향환자예후적독립영향인소,ER-β적양성표체가능여선암급단발골전이환자적예후상관。
Objective To analyze the relationship between ER-β and clinical prognosis by detecting its expression in NSCLC with symptoms of bone metastases at the time of diagnosis. Methods The expression of ER-βin tissues was investigated by immunohistochemistry. The differences between groups were analyzed by chi-square test. The survival rates were calculated using the Kaplan-Meier method. The log-rank method was used for univariate analy-sis, and the Cox regression model was used for multivariate analysis. Results The positive percentage of ER-βex-pressed in 46 NSCLC patients with bone metastases at the time of diagnosis was 78. 3 %. The expression of ER-βhad no difference among groups of sex, age, tumor subtype, number of bone metastases, more than one bone me-tastasis, ALK, CEA. Chi-square test did not find statistical differences of ER-βexpression among groups. Multiva-riate analysis showed that ER-βwas an independent predictor of overall survival (OS) (P=0. 035). Univariate a-nalysis showed that the patients who had ER-β positive expression had longer survival time ( P<0. 05 ) . The pa-tients with lung adenocarcinoma or NSCLC with single bone metastasis who present with ER-β positive expression had a significant superior survival rate to ER-β negative expression patients ( P<0. 05 ) . Conclusion Higher ex-pression of ER-β was found in NSCLC patients with bone metastases at time of diagnosis. The patients with ER-βpositive expression have a favorable prognosis, and it may be an independent prognosis predictor of these patients. In addition, ER-β positive expression may be closely related with OS of NSCLC patients who have single bone me-tastasis or adenocarcinoma.